LIPOXEN TECHNOLOGIES LIMITED
Get an alert when LIPOXEN TECHNOLOGIES LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2026-07-24 (in 2mo)
Last made up 2025-07-10
Watchouts
None on the register
Cash
£44K
+1,718.6% vs 2023
Net assets
-£21M
+7.5% vs 2023
Employees
1
0% vs 2023
Profit before tax
£2M
+0.3% vs 2023
Name history
Renamed 1 time since incorporation
- LIPOXEN TECHNOLOGIES LIMITED 2000-06-15 → present
- LIPOXEN LIMITED 1997-07-10 → 2000-06-15
Net assets
2-year trend · vs Health Care median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | £1,882,865 | £1,853,436 | |
| Operating profit | £1,731,333 | £1,736,845 | |
| Profit before tax | £1,731,333 | £1,736,845 | |
| Net profit | £1,731,333 | £1,736,845 | |
| Cash | £2,428 | £44,155 | |
| Total assets less current liabilities | -£23,184,732 | -£21,447,887 | |
| Net assets | -£23,184,732 | -£21,447,887 | |
| Equity | -£23,184,732 | -£21,447,887 | |
| Average employees | 1 | 1 | |
| Wages | £33,224 | £34,165 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | 92.0% | 93.7% | |
| Net margin | 92.0% | 93.7% | |
| Return on capital employed | -7.5% | -8.1% | |
| Current ratio | 0.00x | 0.00x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- IFRS
- Reporting scope
- Standalone (parent only)
- Auditor
- F. W. Smith, Riches & Co.
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“As a wholly owned-subsidiary of its US-listed parent company, Xenetic Biosciences, Inc (XBIO), the Company ultimately depends upon the Group for funding. Consequently, the directors have received a letter of comfort from XBIO confirming XBIO's intention to provide such level of financial support to the Company for a period of at least 12 months from the date of this Report such that the Company will be able to meet its obligations as they fall due.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 23 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| HILL, Colin William | Secretary | 2014-11-01 | — | — |
| HILL, Colin William | Director | 2011-09-22 | Jun 1945 | British |
| PARSLOW, James | Director | 2018-02-16 | Feb 1965 | American |
Show 23 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| LONERGAN, Denis Cornel | Secretary | 1997-07-10 | 2001-10-31 |
| MARCUS, Bradley | Secretary | 2008-10-30 | 2014-11-01 |
| SAMUEL, Evan James | Secretary | 2001-11-01 | 2002-12-09 |
| ZHURAVSKAYA, Tatiana, Dr | Secretary | 2005-07-01 | 2008-10-30 |
| LUDGATE SECRETARIAL SERVICES LTD | Corporate Secretary | 2003-01-13 | 2005-07-01 |
| SWIFT INCORPORATIONS LIMITED | Corporate Nominee Secretary | 1997-07-10 | 1997-07-10 |
| AXE, Julian Colin, Dr | Director | 2000-05-01 | 2003-07-22 |
| CAMBRIDGE, Allan Charles | Director | 2002-11-05 | 2004-03-19 |
| CHRISTIE, George Allan Gourlay | Director | 1998-12-09 | 2001-12-08 |
| EPENETOS, Agamemnon Antoniou, Dr | Director | 1999-12-14 | 2005-02-04 |
| GENKIN, Dimitry | Director | 2001-04-10 | 2014-05-01 |
| GREGORIADIS, Gregory | Director | 1997-07-10 | 2014-01-28 |
| HENTSCHEL, Christopher Clive, Dr | Director | 2000-05-21 | 2005-09-30 |
| LAING, Peter | Director | 2006-11-01 | 2009-12-21 |
| MACONOCHIE, Stuart Ramsay | Director | 2005-06-30 | 2010-04-20 |
| MAGUIRE, Michael Scott | Director | 2004-04-19 | 2018-10-31 |
| PAPADOPOULOS, Themis | Director | 1998-11-02 | 2005-10-04 |
| PEARL, Howard George | Director | 2000-10-10 | 2001-10-01 |
| RICHARDS, Brian Mansel, Sir | Director | 2005-06-30 | 2014-04-28 |
| TIVENAN, Andrew Simon | Director | 2001-06-18 | 2003-02-28 |
| VOLODIN, Igor | Director | 2004-10-26 | 2007-01-15 |
| ZHEREBTSOV, Andrey | Director | 2002-11-07 | 2003-07-22 |
| ZHURAVSKAYA, Tatiana, Dr | Director | 2002-11-07 | 2010-04-20 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Xenetic Biosciences (Uk) Limited | Corporate entity | Shares 75–100%, Voting 75–100% | 2016-04-06 | Active |
Filing timeline
Last 20 of 173 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2025-10-01 | AA | accounts | Accounts with accounts type full | |
| 2025-08-22 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-06-20 | CH01 | officers | Change person director company with change date | |
| 2024-09-27 | AA | accounts | Accounts with accounts type full | |
| 2024-07-19 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-10-06 | AA | accounts | Accounts with accounts type full | |
| 2023-07-18 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-01-05 | AA | accounts | Accounts with accounts type full | |
| 2022-08-05 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-01-07 | AA | accounts | Accounts with accounts type full | |
| 2021-07-28 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2021-01-13 | AA | accounts | Accounts with accounts type full | |
| 2020-07-27 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2019-10-08 | AA | accounts | Accounts with accounts type full | |
| 2019-09-26 | TM01 | officers | Termination director company with name termination date | |
| 2019-07-29 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2018-10-06 | AA | accounts | Accounts with accounts type full | |
| 2018-08-17 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2018-02-19 | AP01 | officers | Appoint person director company with name date | |
| 2018-01-09 | DISS40 | gazette | Gazette filings brought up to date |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 3
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
-1.6%
£1,882,865 £1,853,436
-
Cash
+1,718.6%
£2,428 £44,155
-
Net assets
+7.5%
-£23,184,732 -£21,447,887
-
Employees
0%
1 1
-
Operating profit
+0.3%
£1,731,333 £1,736,845
-
Profit before tax
+0.3%
£1,731,333 £1,736,845
-
Wages
+2.8%
£33,224 £34,165
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers